Annovis Bio prices $15M public offering of 7.9M shares and warrants

Annovis Bio, Inc.

Offering of 7,895,000 shares and warrants for 7,105,500 shares at combined price $1.90.
Gross proceeds of ~$15M; expected closing May 21, 2026.
Warrants exercisable at $2.25 per share, six-year term from issuance.
Net proceeds for clinical development of buntanetap in Alzheimer's and Parkinson's and working capital.
Canaccord Genuity acting as sole bookrunner.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.